• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » ICH Plans Drug Development Guideline to Boost Trial Design

ICH Plans Drug Development Guideline to Boost Trial Design

May 9, 2022

A planned International Council for Harmonization (ICH) guideline on model-informed drug development (MIDD) will help optimize clinical trial designs, according to ICH, which estimates development of the guideline will be complete in three to four years.

The FDA and other regulators have signaled increased interest in MIDD, an approach that involves creating biological and statistical models from preclinical and clinical data and using these models to develop trial designs. The FDA is currently running a pilot program to spur the development of these models and evaluate their application to trial designs.

Such models can help optimize time and resources in early-phase trials and inform later-phase trials, ICH said in its roadmap to MIDD guideline development.

The approach currently lacks common documentation standards, consistent expectations for model assessments and understanding of terminologies, making it harder to efficiently evaluate model-based submissions, including the quality of the data involved, according to the ICH discussion group charged with developing the guideline.

The discussion group also recommended ICH revise its guideline on Dose Response Studies (E4) to incorporate principles developed for the MIDD guideline.

ICH said it may consider developing additional guidance on MIDD beyond the general principles in approximately three years.

Development and adoption of a new ICH guideline is a five-step process — from initial discussions and draft to final acceptance by ICH member countries — that can take up to a decade to complete.

Read the MIDD roadmap here: https://bit.ly/3yi1HAS.

 

To view more CenterWatch Weekly stories, click here.

Upcoming Events

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 16Oct

    WCG MAGI's Clinical Research Conference 2022 West

  • 16Nov

    17th Annual FDA Inspections Summit

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Options-360x240.png

    Cancer Patients Signal Interest in Less Travel, More Remote Trial Options

  • SurveywBlueBackground-360x240.png

    New Study Shows Trends in Funding, Racial Balance Amidst COVID-19

  • Complexity-360x240.png

    Rising Trial Complexities Create More Payment Problems, Frustrations for Sites

  • Challenge-360x240.png

    BYOD Trials Growing in Popularity, But Unique Tech Challenges Remain

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing